http://www.wallstreetreporter.com Profitable investing ideas Thu, 09 Feb 2012 18:44:44 +0000 en hourly 1 http://wordpress.org/?v=3.1 © http://www.wallstreetreporter.com/?feed=podcast jmarks@wallstreetreporter.com () jmarks@wallstreetreporter.com() 1440 Just another WordPress weblog jmarks@wallstreetreporter.com No no http://www.wallstreetreporter.com/wp-content/plugins/podpress/images/powered_by_podpress.jpg http://www.wallstreetreporter.com 144 144 http://www.wallstreetreporter.com/2010/03/nuvilex-inc-reports-doctors-findings-that-homeopathic-remedies-successfully-treated-swine-flu-in-mexico-city/ http://www.wallstreetreporter.com/2010/03/nuvilex-inc-reports-doctors-findings-that-homeopathic-remedies-successfully-treated-swine-flu-in-mexico-city/#comments Wed, 24 Mar 2010 14:53:56 +0000 admin http://www.wallstreetreporter.com/?p=3406 http://www.wallstreetreporter.com/2010/03/nuvilex-inc-reports-doctors-findings-that-homeopathic-remedies-successfully-treated-swine-flu-in-mexico-city/feed/ 0 http://www.wallstreetreporter.com/2010/02/nuvilex-inc-announces-legacy-biotechnologies%e2%80%99-reme-flu-with-syn-x9-formulation-receives-fda-national-drug-code-number/ http://www.wallstreetreporter.com/2010/02/nuvilex-inc-announces-legacy-biotechnologies%e2%80%99-reme-flu-with-syn-x9-formulation-receives-fda-national-drug-code-number/#comments Tue, 02 Feb 2010 14:00:11 +0000 admin http://www.wallstreetreporter.com/?p=3207 http://www.wallstreetreporter.com/2010/02/nuvilex-inc-announces-legacy-biotechnologies%e2%80%99-reme-flu-with-syn-x9-formulation-receives-fda-national-drug-code-number/feed/ 0 http://www.wallstreetreporter.com/2009/07/nuvilex-inc-otc-bb-nvlx-ceo-interview-2/ http://www.wallstreetreporter.com/2009/07/nuvilex-inc-otc-bb-nvlx-ceo-interview-2/#comments Fri, 17 Jul 2009 14:58:09 +0000 Jack http://www.wallstreetreporter.com/?p=1892 http://www.wallstreetreporter.com/2009/07/nuvilex-inc-otc-bb-nvlx-ceo-interview-2/feed/ 0 00:01:01 Nuvilex, Inc. (OTC BB: NVLX) Martin Schmieg, CEO Flash Player 9 or higher is required to view the chartClick here to download Flash Player now if (typeof(embedWikichart) != "undefined") ... Nuvilex, Inc. (OTC BB: NVLX) Martin Schmieg, CEO Flash Player 9 or higher is required to view the chartClick here to download Flash Player now if (typeof(embedWikichart) != "undefined") {embedWikichart("http://charts.wikinvest.com/WikiChartMini.swf","wikichartContainer_A474181D-A3D1-D587-81B7-C60091FCFAC3","390","245",{"showAnnotations":"true","startDate":"09-12-2008","endDate":"09-06-2009","liveQuote":"true","ticker":"NVLX"});} View the full NVLX chart at Wikinvest Nuvilex Inc., formerly eFoodSafety.com, Inc., is a holding company operating through wholly owned subsidiaries and dedicated to improving and health conditions globally through its technologies. The Company was organized to provide methods and products to ensure the safety of fruits and vegetables being marketed globally. The Company's Knock-Out Technologies, Ltd.(Knock-Out) subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus that kills six bacteria, including E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza and Black Mold. The Companyrsquo;s subsidiary I-Boost, Inc. owns and distributes an immune boosting liquid. In March 2008, the Company formed Cinnechol, Inc. a wholly owned subsidiary engaged in manufacturing a product called Cinnechol 120 count capsules, which is a dietary supplement. TRANSCRIPT WSR: Good day from Wall Street. This is Juan Costello, Senior Analyst with The Wall Street Reporter and joining us today once again is Martin Schmieg, CEO of Nuvilex. The company trades over the counter, ticker symbol is NVLX. Thanks for joining us today for the update. Martin Schmieg: Great to be here Juan. WSR: Now start off by talking to us about the recent release about the company's achieving the first sale of Last Shot Hangover Remedy. Martin Schmieg: We were very excited to announce this week that we have launched and have completed our first sales of the Last Shot Hangover Remedy. Last Shot comes to us as a spin-off product from our Cinnergen metabolism supplement. Users of Cinnergen found when using that product after a night of partying that they were experiencing little or no hangover symptoms. We looked at that very seriously, did some reformulation work, and invented the Last Shot Hangover Remedy, which is an all natural supplement that is calorie free, sugar free, and caffeine free that will, if taken after a night of drinking and before you go to bed, nearly eliminate or eliminate all of your hangover symptoms the next morning. It is going to be introduced and sold through bars and clubs at the point of party, which differentiates us from our competition, and it will be sold at a very reasonable price of $4 per shot. WSR: Nuvilex is a holding company, can you talk about some of your subsidiaries and some of the key products of the subsidiaries as well? Martin Schmieg: Yes, Nuvilex is a holding company. We work in four primary areas. Our supplement subsidiaries are Cinnergen, Cinnechol, and now obviously Last Shot. Those are nutraceutical supplements that cover the areas of diabetes, cholesterol, and now obviously hangover. We also are working in the cleaning area, environmentally friendly and biodegradable cleaners to combat issues like traditional bacteria, it's an anti-germicide working on areas like swine and avian flu. We also come to it with an anesthetics and cosmetics business where we are producing now Cyclosurface 3 cosmetics for a brand named cosmetic manufacturer that distributes through the large box retail environment and we have many other exciting products under development in our pipeline. WSR: In regards to your MA activities, what sort of criteria do you look for companies that you're looking to acquire? Martin Schmieg: We have two primary criterias. Number one is that the products must be able to go from inception to the market in less than 18... CEO,Interview jmarks@wallstreetreporter.com no No http://www.wallstreetreporter.com/2009/06/nuvilex-inc-otc-bb-nvlx-ceo-interview/ http://www.wallstreetreporter.com/2009/06/nuvilex-inc-otc-bb-nvlx-ceo-interview/#comments Tue, 09 Jun 2009 17:13:46 +0000 Jack http://www.wallstreetreporter.com/?p=1674 http://www.wallstreetreporter.com/2009/06/nuvilex-inc-otc-bb-nvlx-ceo-interview/feed/ 0 12:18 Nuvilex, Inc. (OTC BB: NVLX) Martin Schmieg, CEO Flash Player 9 or higher is required to view the chartClick here to download Flash Player now if (typeof(embedWikichart) != "undefined") ... Nuvilex, Inc. (OTC BB: NVLX) Martin Schmieg, CEO Flash Player 9 or higher is required to view the chartClick here to download Flash Player now if (typeof(embedWikichart) != "undefined") {embedWikichart("http://charts.wikinvest.com/WikiChartMini.swf","wikichartContainer_A474181D-A3D1-D587-81B7-C60091FCFAC3","390","245",{"showAnnotations":"true","startDate":"09-12-2008","endDate":"09-06-2009","liveQuote":"true","ticker":"NVLX"});} View the full NVLX chart at Wikinvest Nuvilex Inc., formerly eFoodSafety.com, Inc., is a holding company operating through wholly owned subsidiaries and dedicated to improving and health conditions globally through its technologies. The Company was organized to provide methods and products to ensure the safety of fruits and vegetables being marketed globally. The Company's Knock-Out Technologies, Ltd.(Knock-Out) subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus that kills six bacteria, including E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza and Black Mold. The Companyrsquo;s subsidiary I-Boost, Inc. owns and distributes an immune boosting liquid. In March 2008, the Company formed Cinnechol, Inc. a wholly owned subsidiary engaged in manufacturing a product called Cinnechol 120 count capsules, which is a dietary supplement. CEO,Interview jmarks@wallstreetreporter.com no No